Showing results (31-40 of 1,475) with videos related to
Sort By:
Pageof 148
Neurotoxicology|January 1, 1994
Homogeneity of regional brain lead concentrationsD V Widzowski, D A Cory-SlechtaBrain Research|July 5, 1991
Low level lead exposure increases sensitivity to the stimulus properties of dopamine D1 and D2 agonistsD A Cory-Slechta, D V WidzowskiNeurobehavioral Toxicology|January 1, 1979
Some problems in interpreting the behavioral effects of lead and methylmercuryV G Laties, D A Cory-SlechtaBrain Research|August 1, 1997
The critical role of nucleus accumbens dopamine systems in the mediation of fixed interval schedule-controlled operant behaviorD A Cory-Slechta, R Pazmino, C BareBrain Research|May 18, 2004
Expression of behavioral sensitization to the cocaine-like fungicide triadimefon is blocked by pretreatment with AMPA, NMDA and DA D1 receptor antagonistsR Reeves, M Thiruchelvam, D A Cory-SlechtaNeurotoxicology|January 1, 1993
The effects of lead exposure on learning in a multiple repeated acquisition and performance scheduleJ Cohn, C Cox, D A Cory-SlechtaToxicological Sciences : an Official Journal of the Society of Toxicology|March 12, 2004
Development of behavioral sensitization to the cocaine-like fungicide triadimefon is prevented by AMPA, NMDa, DA D1 but not DA D2 receptor antagonistsR Reeves, M Thiruchelvam, D A Cory-SlechtaThe Journal of Pharmacology and Experimental Therapeutics|September 1, 1985
Lead induction of crop dysfunction in pigeons through a direct action on neural or smooth muscle components of crop tissueI J Boyer, D A Cory-Slechta, V DiStefanoJournal of Neurochemistry|May 1, 1997
Time course and regional basis of Pb-induced changes in MK-801 binding: reversal by chronic treatment with the dopamine agonist apomorphine but not the D1 agonist SKF-82958D A Cory-Slechta, L McCoy, E K RichfieldJournal of Neurochemistry|December 31, 1997
Regional decreases in alpha-[3H]amino-3-hydroxy-5-methylisoxazole-4-propionic acid ([3H]AMPA) and 6-[3H]cyano-7-nitroquinoxaline-2,3-dione ([3H]CNQX) binding in response to chronic low-level lead exposure: reversal versus potentiation by chronic dopamine agonist treatmentL McCoy, E K Richfield, D A Cory-SlechtaPageof 148